At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Partnership
Products and programs
VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
To view the full press release, visit https://ibn.fm/GLFg2
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What will VERAXA Biotech and Ardigen work on together?
The collaboration will first develop AI-enabled tools to identify and prioritize combinations of two targets that may work synergistically in VERAXA’s BiTAC platform. The release says the broader effort is intended to support development of the company’s T-cell engager pipeline and future antibody-drug conjugates.
How does VERAXA plan to use AI in cancer drug development?
VERAXA says AI could help its research and development teams select targets by analyzing large preclinical and clinical datasets. The company specifically points to programs that showed efficacy but were unsuccessful because of toxicity as data that may inform this work.
What is the purpose of VERAXA’s BiTAC platform?
The release describes BiTAC as a platform for T-cell engagers that is designed to improve tumor targeting while reducing toxicity affecting tissues outside the intended target. The collaboration’s initial work is intended to help identify and prioritize dual-target combinations for this platform.
What is an antibody-drug conjugate?
An antibody-drug conjugate is a therapy that links an antibody to a drug payload. The antibody is designed to bind to a particular target, while the attached payload is intended to deliver a therapeutic effect in connection with that target. Its behavior depends on the antibody, linker and payload used.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
- VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
- VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
- VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
- VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
